<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524481</url>
  </required_header>
  <id_info>
    <org_study_id>NISOSTEO20200529</org_study_id>
    <secondary_id>2020-003072-41</secondary_id>
    <nct_id>NCT04524481</nct_id>
  </id_info>
  <brief_title>Osteoporosis and Haemophilia</brief_title>
  <official_title>Osteoporosis Screening in Adult Patients With Haemophilia and Influence of Physical Activity on the Prevalence of Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. Andreas Strauß</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the prevalence of osteoporosis in adult patients with&#xD;
      haemophilia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the prevalence of osteoporosis in adult patients with&#xD;
      haemophilia. Subsequently, the ascertained prevalence of osteoporosis in patients with&#xD;
      haemophilia will be compared to the latest published data of osteoporosis in Germany.&#xD;
      Furthermore, the impact of severity of haemophilia, comorbidities as well as the role of both&#xD;
      physical activity and individual joint condition as influencing factors on the presence of&#xD;
      osteoporosis will be analysed by this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>bone mass/bone density maesurement</measure>
    <time_frame>15 minutes</time_frame>
    <description>All patients with haemophilia of this study will receive a standardised bone density measurement by using the same dual energy X-ray absorptiometry (DXA) device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood sample (Vit. D/Calcium)</measure>
    <time_frame>10 minutes</time_frame>
    <description>The blood samples of all patients with haemophilia will be tested according to the guidelines of the confederation of osteology (DVO). These blood samples are necessary to assess the osteoporosis by measuring the Vitamin-D and Calcium level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>haemophilia related clinical data</measure>
    <time_frame>10 minutes</time_frame>
    <description>All patients with haemophilia record their individual substitution regime and bleeding events in individual patients' diaries. The patients are used to record and submit all necessary information about bleeding events, factor replacement regime. By doing so, the individual treatment regime per week as well as the annual (joint) bleeding rate will be assessed one year retrospectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of physical activity</measure>
    <time_frame>non determinable</time_frame>
    <description>In order to assess the individual level of physical activity, an individual movement profile will be created. For this purpose, the activity of each patient with haemophilia will be recorded by an electronic activity tracker. In addition, the grade of individual physical activity will be assessed on the basis of questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>orthopaedic joint status</measure>
    <time_frame>45 minutes</time_frame>
    <description>The clinical joint status will be examined in all patients with haemophilia by the World Federation Joint Examination Score and Haemophilia Joint Health Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain condition</measure>
    <time_frame>15 minutes</time_frame>
    <description>The pain condition will be examined in terms of pressure pain thresholds. By using an algometer device (Wagner Instruments, USA) with a robe area of 1 cm2 the individual pain sensitivity will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective quality of life and subjective physical performance</measure>
    <time_frame>10 minutes</time_frame>
    <description>The examination of these parameters is carried out by the standardised questionnaires SF-36 (quality of life) and the HEP-Test-Q (subjective physical performance).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>blood samples</measure>
    <time_frame>non determinable</time_frame>
    <description>Blood samples of all PWH will be tested according to the guidelines of the confederation of osteology (DVO). Additionally, the liver's (GGT, GPT, GOT) and parathyroid glands' (PTH) function will be assessed and patient's will also be tested for testosterone-deficiency (testosterone), diabetes (HbA1c) and multiple myeloma (paracentesis).&#xD;
Furthermore these blood samples are necessary to define the immune phenotype (including: soluble mediators such as cytokines and growth factors, as well as the cellular immune composition, immune cell subsets and their detailed phenotype) to examine a possible correlation with the severity of osteoporosis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Medical history</measure>
    <time_frame>10 minutes</time_frame>
    <description>Medical history and pharmacological treatment will be recorded. Based on these parameters the occurrence of secondary osteoporosis will be assessed.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Haemophilia</condition>
  <condition>Bone Mass</condition>
  <arm_group>
    <arm_group_label>Patients with mild haemophilia A or B</arm_group_label>
    <description>(FVIII or IX &gt;5 %, ≥ 18 years' old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with moderate haemophilia A or B</arm_group_label>
    <description>(FVIII or IX 1-5 %, ≥ 18 years' old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with severe haemophilia A or B</arm_group_label>
    <description>(FVIII or IX &lt;1 %, ≥ 18 years' old)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (≥ 18 years of age) suffering from mild (FVIII or IX &gt;5 %), moderate (FVIII&#xD;
        or IX 1-5 %) or severe (FVIII or IX &lt;1 %) haemophilia A or B&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (≥ 18 years of age) suffering from mild (FVIII or IX &gt;5 %), moderate&#xD;
             (FVIII or IX 1-5 %) or severe (FVIII or IX &lt;1 %) haemophilia A or B&#xD;
&#xD;
          -  Submitted written consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from other bleeding diseases&#xD;
&#xD;
          -  PWH without written consent&#xD;
&#xD;
          -  PWH &lt; 18 years of age&#xD;
&#xD;
          -  Secondary osteoporosis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Strauß, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicine of the University of Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Strauß, PD Dr.</last_name>
    <phone>004922828714176</phone>
    <email>andreas.strauss@ukbonn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Northrhine Westfalia</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Strauß, PD Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Strauß, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>PD Dr. Andreas Strauß</investigator_full_name>
    <investigator_title>specialist for orthopaedics and trauma surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The publication of anonymous patient data is not allowed by informed consent.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

